You are visitor number
| The Fluoroquinolone
Toxicity Research Foundation
|
You are visitor number
|
  |
Pediatric Research | See downloads for: Adobe Files |
 |
|
|
|
|
Wed
Oct 22, 2003 2:25pm Subject: Barr Amends Bayer Pact on US Cipro Sales CHICAGO (Reuters) - Barr Laboratories Inc. (BRL.N: Quote, Profile, Research) on Thursday said it will be able to continue to market a generic version of the antibiotic Cipro for children in the United States under an amended agreement with Germany's Bayer Pharmaceutical Corp. (BAYG.DE: Quote, Profile, Research) . Bayer has indicated that it expects to receive exclusivity to market its Cipro drug in the United States for the pediatric market. If granted, exclusivity would expire on June 9, 2004. Cipro, the brand name for the antibiotic ciprofloxacin, is used to treat various types of infections, including urinary tract infections. The market for such drugs racked up sales of about $1.1 million in the 12 months ended July 2003, according to Barr. Barr began selling a generic version of the antibiotic in June 2003 under a license that resulted from a 1997 settlement of a patent challenge. Barr said its amended supply agreement with Bayer covers any period of exclusivity for pediatric use that may be granted to Bayer for the product. In January 1997 Barr and Bayer signed a nonexclusive distribution agreement that provided Barr with the right to begin selling ciprofloxacin products 6 months prior to the expiration of the patent protecting Bayer's Cipro in December 2003. Currently, Barr purchases ciprofloxacin products that are manufactured under Bayer's New Drug Application for Cipro directly from Bayer and sells the drug under its own label.
|
|
 |
|
 |
|
|
|
|